Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An uncommon type of hepatocelluar carcinoma, morphologically characterized by significant fibrosis around the sinusoid-like spaces and atrophy of the tumor trabeculae.
Biomarker and diagnostic research for sclerosing hepatic carcinoma has been reported in the published literature.
No clinical trials have been registered for sclerosing hepatic carcinoma.
17 publications have been identified in PubMed for sclerosing hepatic carcinoma. Research spans Case Report / Case Series (29%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 29% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
4 |
24% |
Laboratory research | 3 | 18% |
Disease patterns and progression | 3 | 18% |
Testing and diagnosis research | 1 | 6% |
Clinical study results | 1 | 6% |
Kumar S (2026). [PMID: 42085064](https://pubmed.ncbi.nlm.nih.gov/42085064/). *J Minim Access Surg*. [Case Report / Case Series]
Kang L (2026). [PMID: 41522204](https://pubmed.ncbi.nlm.nih.gov/41522204/). *Evolution, medicine, and public health*. [Epidemiology / Natural History]
Dimopoulou K (2026). [PMID: 41134331](https://pubmed.ncbi.nlm.nih.gov/41134331/). *Virchows Archiv : an international journal of pathology*. [Clinical Trial Publication]
Kamiya H (2026). [PMID: 41245064](https://pubmed.ncbi.nlm.nih.gov/41245064/). *Radiology case reports*. [Review / Meta-Analysis]
Tsuzaki J (2025). [PMID: 39775861](https://pubmed.ncbi.nlm.nih.gov/39775861/). *Japanese journal of clinical oncology*. [Basic Science / Preclinical]
Furumaya A (2025). [PMID: 41456874](https://pubmed.ncbi.nlm.nih.gov/41456874/). *Histopathology*. [Case Report / Case Series]
Jain D (2025). [PMID: 38729770](https://pubmed.ncbi.nlm.nih.gov/38729770/). *Journal of clinical pathology*. [Epidemiology / Natural History]
Hashimoto S (2025). [PMID: 40271310](https://pubmed.ncbi.nlm.nih.gov/40271310/). *Cureus*. [Case Report / Case Series]
Matsuura T (2025). [PMID: 40610763](https://pubmed.ncbi.nlm.nih.gov/40610763/). *Communications medicine*. [Diagnostic / Biomarker]
Beaufrère A (2025). [PMID: 39572319](https://pubmed.ncbi.nlm.nih.gov/39572319/). *Annales de pathologie*. [Review / Meta-Analysis]
AI-curated news mentioning sclerosing hepatic carcinoma
Updated Sep 14, 2026
A recent study discusses a case of aggressive hepatic carcinoma reclassified as cholangioblastic cholangiocarcinoma, successfully treated with liver transplantation. This retrospective analysis may provide insights into treatment approaches for this rare cancer type.
A rare case report details hepatic carcinoma with epithelial-myoepithelial differentiation and its metachronous intrahepatic recurrence after curative resection. This study contributes to the understanding of rare hepatic tumors and their clinical behavior.